Abstract: Provided is a method for obtaining a macrolide, especially tacrolimus, ascomycin, pimecrolimus, sirolimus, or everolimus, from biomatter.

Abstract: Provided is a method for obtaining a macrolide, especially tacrolimus, from biomatter.

Abstract: A method for converting organic solid waste into humic products and the corresponding apparatus, in which a preliminary aerobic fermentation of the organic solid waste is performed, followed by a second aerobic fermentation of the organic waste in the presence of specific microorganisms in order to provide a basic precursor on which the selective metabolization occurs of specific bacterial strains to provide the humic product.

Abstract: This invention relates to biocontrol formulations suitable for reducing the susceptibility of plants to fungal phytopathogens and for degrading turf thatch. In one aspect of the invention, a culture of strain Streptomyces sp. WYE 53 ATCC 55750 is incorporated into suitable delivery medium and applied to plant seeds and roots. Another aspect of the invention is directed to a composition comprising cultures of strains Streptomyces sp. WYE 53 ATCC 55750 and/or Streptomyces sp. YCED 9 ATCC 55660 and to a method for degrading turf thatch by contacting the turf thach with cultures of strains Streptomyces sp. WYE 53 ATCC 55750 and/or Streptomyces sp. YCED 9 ATCC 55660 which are incorporated into suitable delivery medium.

Abstract: Process for the biotechnological preparation of L-thienylalanines in enantiomerically pure form from 2-hydroxy-3-thienylacrylic acidsL-Thienylalanines are prepared via the hydantoin or the azlactone route. The starting substances used for the biotransformation are 2-hydroxy-3-thienylacrylic acids. The innovative step consists in the transamination of the enol form of the 2-hydroxy-3-thienylacrylic acids to give L-thienylalanines with the aid of biotransformation. The transaminiation is carried out in the presence of L-aspartic acid or L-glutamic acid as amino donor.

Abstract: The present invention relates to certain antibiotic compounds, designated N787-182 compounds herein and derivatives thereof, which are antiparasitic agents, active against insect pests, acari, free-living nematodes and endo- and ectoparasites. This invention also relates to pharmaceutical and other compositions containing such compounds, methods of using such compounds, the microorganism Streptomyces hygroscopicus ATCC 53718 and mutants or genetically transformed or recombinant form thereof, and processes for producing such compounds.

Abstract: This invention relates to tricyclo compounds useful for treatment and prevention of resistance by transplantation, graft-versus-host diseases by medulla ossium transplantation, autoimmune diseases, infectious diseases, and the like, which can be represented by the following formula: ##STR1## to a process for their production, to a pharmaceutical composition containing the same and to a use thereof.

Abstract: Described is a new immunosuppressant, L-687,819, a C-31 demethylated derivative of L-683,795 (FK-523), produced under fermentation conditions utilizing the new mutant microorganism, Streptomyces hygroscopicus subsp. ascomyceticus (Merck Culture Collection MA 6646) ATCC No. 53855, being a blocked mutant of Streptomyces hygroscopicus subsp. ascomyceticus (MA 6475) ATCC No. 14891. The macrolide immunosuppressant is useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow and heart transplants.

Abstract: Described is a new process for producing the immunosuppressant, L-683,742, a C-31 demethylated, derivative of L-683,590 (FK-520), produced under fermentation conditions utilizing the new mutant microorganism, Streptomyces hygroscopicus subsp. ascomyceticus (Merck Culture Collection MA 6646) ATCC No. 53855, being a blocked mutant of Streptomyces hygroscopicus subsp. ascomyceticus (MA 6475) ATCC No. 14891. The macrolide immunosuppressant is useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow and heart transplants.

Abstract: New polyether antibiotic A80789, its acyl ester, alkyl ester, and alkyl ether derivatives, and salts thereof, are useful as antibacterial and anticoccidial agents and increase feed-utilization efficiency in animals. Methods of making A80789 by culture of Streptomyces hygroscopicus NRRL 18513, and combinations of the A80789 compounds with nicarbazin, 4,4'-dinitrocarbanilide, certain napthalenamine and benzenamine compounds and are also provided.

Abstract: Described is a process for producing a new FK-506 antagonist agent, a C-21 hydroxylated analog of FR-900520 under novel fermentation conditions utilizing the novel microorganism, Streptomyces hygroscopicus (Merck Culture Collection MA 6832) ATCC No. 55166. The macrolide antagonist is useful in preventing and/or counteracting accidental or inadvertent FK-506 overdosage in an FK-506 therapeutic program designed to prevent autoimmune diseases or human host rejection of foreign organ transplants, e.g. bone marrow, liver, lung, kidney and heart transplants.

Abstract: An acidic polycyclic ether antibiotic, having structure established by X-ray crystallography, is formed by fermentation of a novel microorganism, Streptomyces hygroscopicus ATCC 53626. This novel antibiotic is useful as an anticoccidial in chickens and as a growth promotant in cattle and swine.

Abstract: A new antitumor antibiotic designated herein as BU-3862T is produced by fermentation of Streptomyces hygroscopicus ATCC 53709. BU-3862T and its diacetyl and dihydro derivatives inhibit the growth of tumors in experimental animals.

Abstract: A new compound, named Substance No. 51262, may be produced by cultivating a suitable microorganism of the genus Streptomyces, especially the new strain SANK 63584 (FERM BP-958). Said compound has herbicidal and growth retardant properties.

Abstract: A new antitumor antibiotic designated BMY-40800 is produced by fermentation of Streptomyces hygroscopicus ATCC 53653. The new compound inhibits the growth of tumors in experimental animals.

Abstract: There is disclosed a series of macrolides isolated from the fermentation broth of a microorganism identified as MA-5000 which morphological analysis reveals to be a strain of Streptomyces hygroscopicus. The compounds' structures are present based upon analytical studies. The compounds have antifungal activity.

Abstract: A new antitumor antibiotic designated BMY-41950 is produced by fermentation of Streptomyces staurosporeus ATCC 55006 or Streptomyces hygroscopicus ATCC 53730. The BMY-41950 antibiotic exhibits both antimicrobial and antitumor activities.

Abstract: The compounds of formula I ##STR1## wherein eitherR.sub.1 is hydroxy,R.sub.2 is allyl or n-propyl andthere is a single bond between the carbon atoms numbered 14 and 15orR.sub.1 is missing,R.sub.2 is allyl andthere is a double bond between the carbon atoms numbered 14 and 15,have interesting immunosuppressant and anti-inflammatory properties.They are obtained by fermentation or synthesis, e.g. by hydrogenation or dehydration.

Abstract: Compounds with acaricidal, insecticidal and anthelmintic activities have the formula: ##STR1## wherein: --X--Y-- is selected from the group consisting of --CH.sub.2 --CH.sub.2 --, --CH.sub.2 --CHOH--, --CH.dbd.CH--, and --CH.sub.2 --C(.dbd.O)--;R.sup.1 is selected from the group consisting of a methyl group, an ethyl group, an isopropyl group, a sec-butyl group and groups of formula --C(CH.sub.3).dbd.CHR.sup.5 in which R.sup.5 is selected from the group consisting of a methyl group, an ethyl group and an isopropyl group;R.sup.2 represents a group of formula --(CH.sub.2).sub.n --C(R.sup.6).dbd.C(R.sup.7)(R.sup.8) in which n is 0, 1 or 2, R.sup.6 and R.sup.7 each is selected from the group consisting of a hydrogen atom and a methyl group and R.sup.8 is selected from the group consisting of a hydrogen atom, a C.sub.1-4 alkyl group, a phenyl group and a phenyl group substituted with at least one substituent selected from the group consisting of halogen, methyl and nitro substitutents;R.sup.

Abstract: A phenyl derivative of pepstatin A, which is much more potent than pepstatin in inhibiting renin enzyme activity and has significantly greater selectivity for renin over pepsin inhibition than does pepstatin, which is useful in treating hypertension and congestive heart failure.

Abstract: A fermentation process for preparing staurosporine, a known antibiotic, employing a heretofore unknown micrrorganism is described, said microorganism being classified as a novel strain of Streptomyces hygroscopicus being and herein designated Streptomyces hygroscopicus strain C39280-450-9 (ATCC 53730).

Abstract: This invention relates to tricyclo compounds useful for treatment and prevention of resistance by transplantation, graft-versus-host diseases by medulla ossium transplantation, autoimmune diseases, infectious diseases, and the like, which can be represented by the following formula: ##STR1## to a process for their production, to a pharmaceutical composition containing the same and to a use thereof.

Abstract: Novel pseudo-aminosugars, or 5-amino-1-hydroxymethyl-1,2,3,4-cyclohexanetetrol, their production and use.These pseudo-aminosugars exhibit excellent .alpha.-glucosidase inhibitory activity and are useful for hyperglycemic symptoms and various disorders caused by hyperglycemia.

Abstract: This invention relates to tricyclo compounds useful for treatment and prevention of resistance by transplantation, graft-versus-host diseases by medulla ossium transplantation, autoimmune diseases, infectious diseases, and the like, which can be represented by the following formula: ##STR1## to a process for their production, to a pharmaceutical composition containing the same and to a use thereof.

Abstract: The present invention relates to a novel polyether ionophore antibiotic of the formula ##STR1## and its pharmaceutically acceptable salts. The compound of formula I and its salts exhibit activity as an antibacterial agent and as an anticoccidial agent.

Abstract: There is disclosed a series of macrolides isolated from the fermentation broth of a microorganism identified as MA-5000 which morphological analysis reveals to be a strain of Streptomyces hygroscopicus. The compound's structure is presented based upon analytical studies. The compound has antifungal activity.

Abstract: Antibiotic Bu-2659 complex, containing components A, B, C, D and E, is produced by cultivation of Streptomyces hygroscopicus Strain No. J296-21, ATCC No. 39150.

Abstract: There is disclosed a macrolide isolated from the fermentation broth of a microorganism identified as MA-5285 which morphological analysis reveals to be a strain of Streptomyces hygroscopicus. The compound's structure is presented based upon analytical studies. The compound has insecticidal and antiparasitic activity.

Abstract: Zinc complexes of glycolic monovalent monoglycoside polyether antibiotics are provided for use as coccidiostats and growth-promoting agents when administered to poultry and for use as active agents for improving cardiovascular function in animals.Zinc complexes of the type disclosed can be prepared by adding soluble zinc salt to a fermentation beer containing the glycolic monovalent monoglycoside polyether antibiotic to thereby form an insoluble, recoverable biomass containing the desired zinc antibiotic complex.

Abstract: The present invention provides a process for obtaining cholesterol oxidase, wherein Streptomyces griseofuscus DSM 40191, Streptomyces hygroscopicus 40771, Streptomyces acidomyceticus DSM 40798 and/or Arthrobacter paraffinens DSM 312 are cultured and the enzyme obtained from the culture supernatant and/or the cells.

Abstract: New tylosin derivatives having at least one acyl group at the 3- and 4"-positions of tylosin, and the acid addition salts thereof, which inhibit the growth of various microorganisms including drug-resistant bacterial isolants and which produce high blood levels through oral administration are produced by a biochemical reaction using the microorganisms of the genus Streptomyces which are selected for their newly-found ability to acylate at least one of the 3- and 4"-positions of macrolide antibiotics; they are recovered from the reacted mixture by conventional methods for recovering macrolide antibiotics.

Abstract: This disclosure describes a new antibiotic designated BL580.DELTA. produced in a microbiological fermentation under controlled conditions using a new strain of Streptomyces hygroscopicus and mutants thereof. This new antibiotic is an active anticoccidial agent.

Abstract: A novel antibiotic substance SF-1540 and a process for preparing the same which comprises culturing a substance SF-1540-producing microorganism belonging to the genus Streptomyces in a medium and isolating and recovering the substance SF-1540 from a cultured broth; a novel derivative of the substance SF-1540 and a process for preparing the same which comprises treating said antibiotic substance SF-1540 with methanol to form the corresponding antibiotic substance SF-1540 derivative.